FDA Grants Seven Years' Market Exclusivity to Eagle Pharmaceuticals' Ryanodex for the Treatment of Malignant Hyperthermia

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company")

today confirmed that the U.S. Food and Drug Administration (FDA) has granted seven years of market exclusivity in the U.S. to Ryanodex^® (dantrolene sodium) for Injectable Suspension for the treatment of malignant hyperthermia (MH). Ryanodex was designated an orphan drug in August 2013 and was approved by the FDA in July 2014 for this indication. "We are very pleased that the anticipated market exclusivity for this important orphan drug has been formally granted," said Scott Tarriff, President and Chief Executive Officer. "The response to Ryanodex has been positive since its launch late last August, and we look forward to further market penetration going forward."